A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis.
Latest Information Update: 17 May 2024
At a glance
- Drugs Fenebrutinib (Primary) ; Ocrelizumab
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms FENtrepid
- Sponsors Roche
- 30 Mar 2024 Planned number of patients changed from 946 to 985.
- 13 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Oct 2022 Planned End Date changed from 17 May 2028 to 18 Dec 2026.